“CEO of AbCellera Carl Hansen says that if human testing of his company’s antibodies is successful, AbCellera will be in a position to mass manufacture, scale up, and deliver antibodies to the broad population for preventative use against COVIDcampaign-pages/bispecifics/-19 within months.”
Read full coverage on BNN Bloomberg.